---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-073937"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:16:12.249197+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protara Q2 net loss $15M; cash $145.6M into mid-2027; key trial readouts set

## Summary
- Q2 2025 net loss $15.0M ($0.35/shr) vs $9.5M ($0.45/shr) in Q2 2024; R&D spend up to $10.8M.
- Cash, equivalents and investments $145.6M at June 30, expected to fund operations into mid-2027.
- Interim data from ~25 BCG-unresponsive NMIBC patients (ADVANCED-2 trial) expected at 1Q 2026 medical conference.
- First patient in THRIVE-3 Phase 3 registrational trial of IV Choline Chloride on track for 3Q 2025.
- Appointed William Conkling as Chief Commercial Officer in June 2025; added to Russell 3000 Index.

## SEC filing metadata
- accession: 0001213900-25-073937
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390025073937/0001213900-25-073937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390025073937/ea0250509-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-073937
- JSON: https://secwatch.observer/filing/0001213900-25-073937.json
- Plain text: https://secwatch.observer/filing/0001213900-25-073937.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.